RNA polymerase inhibitor enisamium for treatment of moderate COVID-19 patients: a randomized, placebo-controlled, multicenter, double-blind phase 3 clinical trial
O. Holubovska, P. Babich, A. Mironenko, J. Milde, Y. Lebed, H. Stammer, L. Mueller, View ORCID ProfileA.J.W. te Velthuis, V. Margitich, A. Goy
doi: https://doi.org/10.1101/2022.08.21.22279036
O. Holubovska
1O.O. Bogomolets National Medical University, T. Shevchenko blvd., 13, Kyiv, Ukraine
P. Babich
2State Expert Center, Smolenska str., 10, Kyiv, Ukraine
A. Mironenko
3L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of the NAMS of Ukraine, Department of respiratory and other viral infections, Amosova str 5a, 03083, Kyiv, Ukraine
J. Milde
4Pharmalog Institut für klinische Forschung GmbH, Ismaning, Germany
Y. Lebed
5Pharmaxi LLC, Filatova Str., 10A, office 3/20, 01042, Kyiv, Ukraine
H. Stammer
4Pharmalog Institut für klinische Forschung GmbH, Ismaning, Germany
L. Mueller
6Regenold GmbH, Zöllinplatz 4, D-79410 Badenweiler, Germany
A.J.W. te Velthuis
7Department of Molecular Biology, Princeton University, Washington Road, 08544 NJ, United States
V. Margitich
8Farmak Joint Stock Company, Kyrylivska Street, 04080, Kyiv, Ukraine
A. Goy
8Farmak Joint Stock Company, Kyrylivska Street, 04080, Kyiv, Ukraine
Data Availability
The data analyzed and presented in this study are available from P.B. and V.M. on reasonable request, providing the request meets local ethical and research criteria. Patient data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. The study protocol is available upon request.
Posted August 23, 2022.
RNA polymerase inhibitor enisamium for treatment of moderate COVID-19 patients: a randomized, placebo-controlled, multicenter, double-blind phase 3 clinical trial
O. Holubovska, P. Babich, A. Mironenko, J. Milde, Y. Lebed, H. Stammer, L. Mueller, A.J.W. te Velthuis, V. Margitich, A. Goy
medRxiv 2022.08.21.22279036; doi: https://doi.org/10.1101/2022.08.21.22279036
RNA polymerase inhibitor enisamium for treatment of moderate COVID-19 patients: a randomized, placebo-controlled, multicenter, double-blind phase 3 clinical trial
O. Holubovska, P. Babich, A. Mironenko, J. Milde, Y. Lebed, H. Stammer, L. Mueller, A.J.W. te Velthuis, V. Margitich, A. Goy
medRxiv 2022.08.21.22279036; doi: https://doi.org/10.1101/2022.08.21.22279036
Subject Area
Subject Areas
- Addiction Medicine (353)
- Allergy and Immunology (675)
- Anesthesia (182)
- Cardiovascular Medicine (2675)
- Dermatology (226)
- Emergency Medicine (404)
- Epidemiology (12293)
- Forensic Medicine (10)
- Gastroenterology (768)
- Genetic and Genomic Medicine (4144)
- Geriatric Medicine (388)
- Health Economics (683)
- Health Informatics (2685)
- Health Policy (1008)
- Hematology (365)
- HIV/AIDS (857)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (443)
- Neurology (3927)
- Nursing (212)
- Nutrition (584)
- Oncology (2065)
- Ophthalmology (592)
- Orthopedics (243)
- Otolaryngology (306)
- Pain Medicine (251)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1126)
- Primary Care Research (461)
- Public and Global Health (6566)
- Radiology and Imaging (1415)
- Respiratory Medicine (874)
- Rheumatology (413)
- Sports Medicine (344)
- Surgery (454)
- Toxicology (54)
- Transplantation (189)
- Urology (169)